News Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Delayed Nasdaq Other stock markets 09:50:01 2024-04-24 am EDT			5-day change	1st Jan Change
0.6629 ^USD	-0.39%		-7.53%	-15.33%

Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ
Apr. 04	Traws Pharma, Inc. Announces Chief Executive Office Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Traws Pharma, Inc. Announces Chief Executive Office Changes	Apr. 04	CI
Traws Pharma, Inc. Announces Board Changes	Apr. 04	CI
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	Apr. 02	MT
Transcript : Onconova Therapeutics, Inc. - M&A Call	Apr. 02
Traws Pharma Announces New Employee Inducement Grants	Apr. 02	AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company	Apr. 02	AQ
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc	Apr. 02	CI
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	Apr. 01	CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines	Mar. 31	CI
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024	Mar. 08	AQ
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	Dec. 12	AQ
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	Dec. 12	CI
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's	Dec. 11	AQ
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s	Dec. 08	AQ
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s	Dec. 08	CI
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference	Nov. 29	AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference	Nov. 28	AQ
Transcript : Onconova Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Summary

Filters